SCHOTT Pharma breaks ground in Hungary
SCHOTT Pharma hosted an event to mark the construction start of the new production hub for prefillable glass syringes in Lukácsháza, Hungary. The company plans to invest a double-digit million Euro amount and create 120 new jobs at the site where work is scheduled for completion in 2024.
“With this move, we are staying one step ahead in providing high-value solutions to store biologics, vaccines and the latest generation of mRNA-based medications,” said Andreas Reisse, CEO at SCHOTT Pharma. The company’s investment is supported by funding from the local government.
“With the new production in Lukácsháza, we are adding a second production hub for glass PFS to SCHOTT Pharma’s global manufacturing network,” said Christian Helbig, Vice President for Prefillable Glass Syringes at SCHOTT Pharma. In line with the company’s philosophy of maintaining the highest quality, it will feature fully automated manufacturing processes, cutting-edge machinery, as well as an advanced camera-controlled inspection system.
The high-quality PFS not only offer a stable, long-term storage solution for drugs, but also a safe and convenient delivery system for patients and clinicians. “With our PFS system, we are eliminating almost all drug injection preparation steps and thereby reducing the risk of medical errors and contaminations. This plays a vital role in the safety of health care professionals and patients,” said Mr Helbig. SCHOTT Pharma offers a broad portfolio of different syringe formats and pre-tested components, such as closures and plungers that pharma companies can choose from.
Image: SCHOTT Pharma breaks ground for cutting-edge production in Hungary. Source: SCHOTT
Image: SCHOTT Pharma’s prefillable glass syringes can store biologics, vaccines and the latest generation of mRNA-based medications. Source: SCHOTT Pharma/Oana Szekely.
